FDMT

FDMT R&D to Revenue

229.67%Fiscal year

Period ending:

FDMT FY R&D/Revenue%
FDMT FY R&D/Revenue427700.30%-45681.16%
2017-12-312025-12-31

Source: Financial Modeling Prep (FMP). Annual fiscal periods. Dates are period ends; a fiscal year may differ from a calendar year.

FDMT r&d to revenue history

R&D spending as percentage of revenue. The available annual fiscal periods series contains 9 observations from Dec 31, 2017 to Dec 31, 2025.

4D Molecular Therapeutics Inc R&D to Revenue — Annual fiscal periods
Period endingR&D to Revenue
229.6659%
381,889.1892%
468.5422%
2,564.813%
340.1708%
389.6415%
627.7555%
129.9505%
234.4214%

Compare r&d to revenue

All FDMT financial metrics · FDMT stock overview · How to interpret financial metrics

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.